Alpha Tau to Participate in the H.C. Wainwright 26th Annual Global Investment Conference, the Sidoti Small-Cap Virtual Investor Conference, the Redburn Atlantic and Rothschild & Co 2024 Radiopharma Conference, and the Lytham Partners Fall 2024 Investor Con
22 Agosto 2024 - 7:30AM
Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ:
DRTS, DRTSW), the developer of the innovative alpha-radiation
cancer therapy Alpha DaRT®, today announced
that CFO Raphi
Levy will present a corporate overview and
update at the H.C. Wainwright 26th Annual Global
Investment Conference on September 10th, 2024 and in the Sidoti
Virtual Investor Conference on September 18-19th, 2024 and will
participate in the Redburn Atlantic and Rothschild & Co 2024
Radiopharma Conference on September 26th, 2024 and the Lytham
Partners Fall 2024 Investor Conference on October 1st, 2024.
Event: |
H.C. Wainwright 26th Annual Global Investment Conference |
Date: |
September 10, 2024 |
Time: |
12:00 – 12:30PM EST |
Location: |
New York, NY |
Event: |
Sidoti Small-Cap Virtual Investor Conference |
Date: |
September 19, 2024 |
Time: |
11:30AM – 12:00PM EST |
Location: |
Virtual |
Event: |
Redburn Atlantic and Rothschild & Co 2024 Radiopharma
Conference |
Date: |
September 26, 2024 |
Time: |
8:30AM – 2:30PM EST |
Location: |
New York, NY |
Event: |
Lytham Partners Fall 2024 Investor Conference |
Date: |
October 1, 2024 |
Time: |
8:00AM – 7:00PM EST |
Location: |
Virtual |
Mr. Levy will be available for 1x1 investor meetings at all
conferences. Please reach out to your H.C. Wainwright, Sidoti,
Rothschild & Co, or Lytham Partners representatives to
schedule.
About Alpha Tau Medical Ltd.
Founded in 2016, Alpha Tau is an Israeli oncology therapeutics
company that focuses on research, development, and potential
commercialization of the Alpha DaRT for the treatment of solid
tumors. The technology was initially developed by Prof. Itzhak
Kelson and Prof. Yona Keisari from Tel Aviv University.
About Alpha DaRT®
Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is
designed to enable highly potent and conformal alpha-irradiation of
solid tumors by intratumoral delivery of radium-224 impregnated
sources. When the radium decays, its short-lived daughters are
released from the sources and disperse while emitting high-energy
alpha particles with the goal of destroying the tumor. Since the
alpha-emitting atoms diffuse only a short distance, Alpha DaRT aims
to mainly affect the tumor, and to spare the healthy tissue around
it.
Investor Relations Contact: IR@alphatau.com
Alpha Tau Medical (NASDAQ:DRTS)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
Alpha Tau Medical (NASDAQ:DRTS)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024